Lymphoma
Mother and baby fine after first reported use of immune-checkpoint inhibitor during pregnancy
ASH 2021 Focus on CAR T-Cell Therapy Podcast
SEQUOIA: Zanubrutinib meets primary endpoint for treatment-naïve CLL/SLL
Most re-hospitalisations within first month from CAR T-cell infusion
CD22-directed CAR T-cell therapy safe and well-tolerated in R/R LBCL
High rate of rapid and complete responses with axi-cel in high-risk large B-cell lymphoma
Second-line tisa-cel similar to standard-of-care for R/R aggressive non-Hodgkin lymphoma
Axi-cel improved event-free survival in R/R DLBCL
Novel anti-CD19 plus lenalidomide prolonged survival in R/R DLBCL
Axi-cel more effective but tisa-cel less toxic in DLBCL
POLARIX: Novel regimen superior to R-CHOP in DLBCL
Novel non-invasive biomarker ctDNA shows value in CNS lymphoma
Liso-cel superior to standard-of-care as second-line therapy in large B-cell lymphoma
CIRS is predictive of outcomes in CAR T-cell recipients with R/R DLBCL
Axi-cel more effective but tisa-cel less toxic in large B-cell lymphoma
Axi-cel improved event-free survival in relapsed/refractory large B-cell lymphoma
Comparable outcomes with second-line tisa-cel versus standard-of-care for relapsed/refractory aggressive NHL
Improved QoL with axi-cel versus standard-of-care in R/R LBCL
Progression of large B-cell lymphoma cut 27% by addition of polatuzumab vedotin
After large B-cell lymphoma relapse, Gilead’s CAR T treatment hikes event-free survival by 60%
Mutational analyses are predictive in malignant lymphomas
Low numbers of M2 macrophages in tumour microenvironment associated with superior response to immunotherapy in Hodgkin lymphoma
Younger non-Hodgkin lymphoma survivors at higher risk for age-related diseases
Limited evidence supports many hematopoietic stem cell transplant guidelines
Lung cancer, non-Hodgkin lymphoma biggest contributors to life-years lost to cancer in transplant patients
COVID-19 patients with B-cell malignancies may deteriorate on bamlanivimab-etesevimab therapy
Novel dose-dense multidrug regimen shows promise in relapsed/refractory Hodgkin lymphoma
Escalating the ESCALADE trial: untreated diffuse large B-cell lymphoma
Immuno-oncology agents are effective in treating classic Hodgkin’s lymphoma
MATRix with ASCT: best long-term survival for primary CNS lymphoma
Naratuximab emtansine + rituximab safe and effective in diffuse large B-cell lymphoma
The journey ahead for CAR T-cell therapy in r/r follicular lymphoma
ZUMA-5 vs SCHOLAR-5: Axicabtagene ciloleucel significantly improves FL outcome
Promising chemo-free treatment options in r/r DLBCL
Pfizer/BioNTech COVID-19 vaccine seems effective, safe in HCT, CART therapy patients
Add-on copanlisib prolongs life in relapsed, indolent non-Hodgkin lymphoma
CD58 aberrations limit durable responses to CD19 CAR T-cell therapy
Anti-CD19 CAR T-cell therapy in relapsed/refractory indolent NHL
More complicated course of COVID-19 in leukaemia patients
Burkitt lymphoma prognostic index may lead to more targeted therapy
Origins of blood cancer traced to early childhood, decades before diagnosis
Tazemetostat provides objective responses in follicular lymphoma, epithelioid sarcoma
Diagnosing Hodgkin lymphoma in kids requires biopsy, immunohistochemistry: guidelines
Double-targeted CAR-T cell immunotherapy promising for refractory non-Hodgkin lymphoma
PET-stratification can omit radiotherapy in early-stage unfavourable Hodgkin lymphoma
Pembrolizumab improves PFS for relapsed/refractory Hodgkin lymphoma
Promising first-in-human trial of epcoritamab in B-NHL
Zanubrutinib versus ibrutinib in Waldenström macroglobulinaemia
Venetoclax + navitoclax promising for R/R ALL or LL
